Navigation Links
Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
Date:2/20/2008

g new and innovative technologies to further its growth in the emerging biologics and regenerative medicine industry."

Total revenue for the three months ended December 31, 2007 increased 6% to $26.9 million from $25.4 million for the fourth quarter of 2006. Core product revenue increased 17% to $17.7 million for the three months ended December 31, 2007 as compared to revenue of $15.1 million from core products in the fourth quarter of 2006. Gross margin improved to 53.5% in the fourth quarter of 2007 as compared to 47.6% in the fourth quarter of 2006.

Diluted earnings per share for the three months ended December 31, 2007 was $.04 on net income of $.8 million as compared to net income of $.1 million for the three months ended December 31, 2006.

Osteotech will host a conference call on Wednesday, February 20, 2008 at 9:00 a.m. Eastern Time during which management will discuss full year and fourth quarter financial results. You are invited to listen to the conference call by dialing 1-706-643-1624. The conference call will also be simultaneously webcast at http://www.osteotech.com. Automated playback will be available two hours after completion of the live call, through midnight, Wednesday, March 5, 2008, by dialing 1-706-645-9291 and indicating access code 34462919.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, this press release or the conference call, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not his
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
4. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
7. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
10. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
11. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 BioHealth Innovation, Inc. (BHI), ... innovations and increasing access to early-stage funding in ... capitalist, Tania Fernandez , Ph.D., has joined the ... be a member of the management team for a ... $50 million in seed and early-stage equity investments to ...
(Date:9/30/2014)... September 30, 2014 The custom stainless ... Boston Product Show 2014. The Boston Area Chapter of ... 23rd annual, day-long event for Wed., Oct. 1 at ... to be the largest in ISPE Boston’s long history, ... of 3,000 attendees expected. , HOLLOWAY AMERICA President ...
(Date:9/30/2014)... On September 11, Pharma IQ conducted an ... of a session that he will lead on “Stem Cells” ... February 17-18, 2015 in London. In the interview posted ... Sherley to respond to several questions on the current state ... stem cell toxicity, and future trends in the use of ...
(Date:9/30/2014)... Pittsburgh PA (PRWEB) September 30, 2014 ... Nurses ( IACRN), a non-profit organization based ... Clinical Research Excellence and Safety (ACRES), a ... of a strategic alliance agreement, setting the stage ... is to enhance clinical research quality and safety ...
Breaking Biology Technology:Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... InNexus,Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX ... commercializing the next,generation of monoclonal antibodies based on ... Morhet, CEO and Chairman, will,present at the 7th ... Mr. Morhet,s thirty-minute presentation to potential investors ...
... NOVATO, Calif., Oct. 28 , Financial Highlights ($ in millions, except per share data), Item ... Q3 2007 Comparison Total BioMarin Revenue $72.6 ... Product Revenue $33.3 ... $38.2 ...
... DiaGenic ASA (OSL:DIAG),today announced that it has ... leading panEuropean provider of gene expression-based,diagnostic testing ... following,CE marking scheduled in early2009, DiaGenic will ... in Europe its innovative blood-based,gene-expression diagnostic test ...
Cached Biology Technology:InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum 2BioMarin Announces Third Quarter 2008 Financial Results 2BioMarin Announces Third Quarter 2008 Financial Results 3BioMarin Announces Third Quarter 2008 Financial Results 4BioMarin Announces Third Quarter 2008 Financial Results 5BioMarin Announces Third Quarter 2008 Financial Results 6BioMarin Announces Third Quarter 2008 Financial Results 7BioMarin Announces Third Quarter 2008 Financial Results 8BioMarin Announces Third Quarter 2008 Financial Results 9BioMarin Announces Third Quarter 2008 Financial Results 10BioMarin Announces Third Quarter 2008 Financial Results 11BioMarin Announces Third Quarter 2008 Financial Results 12Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests 2
(Date:9/30/2014)... Ecker, a Salk professor and Howard Hughes Medical ... have been named recipients in the 2014 round ... (NIH) through the BRAIN (Brain Research through Advancing ... The grant, announced September 30, provides more than ... over three years. , The BRAIN Initiative, launched ...
(Date:9/30/2014)... available in German . ... most expensive foods in the world. Because they grow underground, ... the distinctive smell of truffles is not only of interest ... the direction of the Goethe University Frankfurt have discovered that ... bacteria which are trapped inside truffle fruiting bodies. , White ...
(Date:9/30/2014)... pregnanteven with IVF? Here,s some hope: A new research ... The FASEB Journal , explains how scientists developed ... PAWP, which induced embryo development in human and mouse ... by the sperm cell during fertilization. , "We believe ... paradigm shift in our understanding of human fertilization by ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... Sanford-Burnham Medical Research Institute, a nonprofit research institution ... the world, and Intrexon Corporation, a leading synthetic ... accelerate stem cell research. Under the agreement, Sanford-Burnham ... and gene regulation technologies that are not currently ...
... This press release is available in Spanish ... scientists are developing strategies to help livestock producers control ... in the United States. An economic ... (ARS) Agroecosystem Management Research Unit (AMRU) in Lincoln, Neb., ...
... drugs are taken off the market and a major reason ... reporting the development of a new way to predict those ... which could save patients from severe side effects and save ... of Chemical Information and Modeling . Yoshihiro Yamanishi and ...
Cached Biology News:Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research 2Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research 3Treating stable flies in pastures 2
Taq DNA polymerase, 10,000U...
... is the most thoroughly characterized enzyme available ... its overall utility and efficacy. , Its ... PCR applications. , It is QC ... AmpliTaq DNA Polymerase is a 94 kDa ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... GCpro Taq DNA Polymerase is a versatile ... for all PCR applications. GCpro Taq DNA ... expressed in E. coli, containing the DNA ... enzyme includes a highly processive 5'-3' DNA ...
Biology Products: